Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of (+)-Epibatidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 known ✓ | P36544 | 4/20 | 1.00 |
| ▸ | CHRNB4 known ✓ | P30926 | 4/20 | 0.97 |
| ▸ | CHRNA3 known ✓ | P32297 | 4/20 | 0.97 |
| ▸ | CHRNA1 known ✓ | P02708 | 1/20 | 0.97 |
| ▸ | CHRNG known ✓ | P07510 | 1/20 | 0.97 |
| ▸ | CHRNB1 known ✓ | P11230 | 1/20 | 0.97 |
| ▸ | CHRND known ✓ | Q07001 | 1/20 | 0.97 |
| ▸ | CHRNB2 | P17787 | 7/20 | 0.97 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.97 |
| ▸ | CHRNA2 | Q15822 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | HPGD | P15428 | 1/20 | 0.97 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Epibatidine SCHEMBL5969577 | 1.00 | CHRNA7 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL9070584 | 0.98 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL316977 | 0.98 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL316978 | 0.98 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Epibatidine SCHEMBL29390446 | 0.98 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| (-)-Epibatidine SCHEMBL2500147 | 0.98 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| (+)-Epibatidine SCHEMBL6264689 | 0.97 | CHRNB2 (0.97) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| Homoepibatidine SCHEMBL29711361 | 0.89 | CHRNB2 (1.00) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL7663147 | 0.83 | CHRNB2 (0.72) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 | |
| SCHEMBL13596272 | 0.83 | CHRNB2 (0.72) | CHRNA7CHRNB2CHRNA4CHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0889731-B1 | INJECTABLE THERAPY FOR CONTROL OF MUSCLE SPASMS AND PAIN RELATED TO MUSCLE SPASMS | ALLERGAN INC (US) | 2004-11-24 | — | — | EP | claimed |
| EP-1773779-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITE LAVAL (CA) | 2007-04-18 | — | — | EP | disclosed |
| US-7108857-B2 | Therapy for injured muscles | ALLERGAN, INC. (US) | 2006-09-19 | — | — | US | disclosed |
| WO-2006005195-A1 | NICOTINIC RECEPTOR AGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | UNIVERSITé LAVAL (CA) | 2006-01-19 | — | — | WO | disclosed |
| US-20050281846-A1 | Therapy for injured muscles | ALLERGAN, INC. (US) | 2005-12-22 | — | — | US | disclosed |
| EP-0889731-B1 | INJECTABLE THERAPY FOR CONTROL OF MUSCLE SPASMS AND PAIN RELATED TO MUSCLE SPASMS | ALLERGAN INC (US) | 2004-11-24 | — | — | EP | disclosed |
| WO-1996006093-A1 | 7-AZABICYCLO[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS CHOLINERGIC RECEPTOR LIGANDS | UNIVERSITY OF VIRGINIA (US) | 1996-02-29 | — | — | WO | disclosed |
| WO-1994022868-A1 | 7-AZABICYCLO-[2.2.1]-HEPTANE AND -HEPTENE DERIVATIVES AS ANALGESICS AND ANTI-INFLAMMATORY AGENTS | UNIVERSITY OF VIRGINIA (US) | 1994-10-13 | — | — | WO | disclosed |